Scotiabank lowered the firm’s price target on Kura Oncology (KURA) to $18 from $22 and keeps a Sector Perform rating on the shares. The firm adjusted its price target on the stock following recent lackluster mNPM-1 revumenib results reported by Syndax (SNDX) as well as the announced deal terms with Kyowa Kirin (KYKOF), the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KURA:
- Kura Oncology price target lowered to $34 from $37 at Wedbush
- Kura selling off on loss of acquisition premium, says TD Cowen
- Kura deal with Kyowa detracts from takeout narrative, says Mizuho
- Kura Oncology price target lowered to $28 from $32 at Jefferies
- Kura Oncology price target raised to $37 from $32 at H.C. Wainwright